Eucrates Biomedical Acquisition Corp.
EUCR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $0 |
| SG&A Expenses | $0 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 |
| Operating Expenses | $1 | $1 | $0 |
| Operating Income | -$1 | -$1 | $0 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $3 | $5 | $0 |
| Pre-Tax Income | $2 | $4 | $0 |
| Tax Expense | -$3 | $0 | $0 |
| Net Income | $6 | $4 | $0 |
| % Margin | – | – | – |
| EPS | 1.86 | 1.28 | 0.001 |
| % Growth | 45.3% | 213,233.3% | – |
| EPS Diluted | 1.86 | 0.28 | 0.001 |
| Weighted Avg Shares Out | 3 | 3 | 13 |
| Weighted Avg Shares Out Dil | 3 | 13 | 13 |
| Supplemental Information | – | – | – |
| Interest Income | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | -$2 | -$5 | $0 |
| EBITDA | -$3 | -$5 | $0 |
| % Margin | – | – | – |